The changing landscape of diabetes care is experiencing a exciting shift, driven by innovative incretin-based therapies. Presently, semaglutide has gained considerable traction, but rival medications like tirzepatide, retatrutide, and cagrilintide are set to alter the prospects. Tirzepatide, a du